Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 26, Issue 12, 2016, Pages 1112-1119

  Galasso, S ^a   Facchinetti, A ^a   Bonora, B M ^a   Mariano, V ^a   Boscari, F ^a   Cipponeri, E ^a   Maran, A ^a   Avogaro, A ^a   Fadini, G P ^a   Bruttomesso, D ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Basal bolus therapy; Glycaemic control; Insulin degludec; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETES TREATMENT SATISFACTION QUESTIONNAIRE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOGLYCAEMIA FEAR SURVEY 2 QUESTIONNAIRE; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; BLOOD; CHEMICALLY INDUCED; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; ITALY; METABOLISM; MIDDLE AGED; PATIENT SATISFACTION; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; BIOMARKERS; BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN, LONG-ACTING; ITALY; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84994804587     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2016.08.002     Document Type: Article

References (30)

1. [1] Vajo, Z., Fawcett, J., Duckworth, W.C., Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 22 (2001), 706–717.
2. [2] Pettus, J., Santos Cavaiola, T., Tamborlane, W.V., Edelman, S., The past, present, and future of basal insulins. Diabetes Metab Res Rev, 2015, 10.1002/dmrr.2763.
3. [3] Bolli, G.B., Andreoli, A.M., Lucidi, P., Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. Diabetes Technol Ther 13:Suppl. 1 (2011), S43–S52.
4. [4] Heise, T., Pieber, T.R., Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 9 (2007), 648–659.
5. [5] Porcellati, F., Rossetti, P., Busciantella, N.R., Marzotti, S., Lucidi, P., Luzi, S., et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 30 (2007), 2447–2452.
6. [6] Ashwell, S.G., Gebbie, J., Home, P.D., Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Diabet Med 23 (2006), 46–52.
7. [7] Ashwell, S.G., Gebbie, J., Home, P.D., Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med 23 (2006), 879–886.
8. [8] Perea, V., Amor, A., Gimenez, M., Blanco, J., Conget, I., Glycemic variability measures in a group of subjects with type 1 diabetes and repeated severe and non-severe hypoglycemia. J Diabetes Sci Technol 7 (2013), 289–290.
9. [9] Reddy, M., Godsland, I.F., Barnard, K.D., Herrero, P., Georgiou, P., Tomson, H., et al. Glycemic variability and its impact on quality of life in adults with type 1 diabetes. J Diabetes Sci Technol 10 (2015), 60–66.
10. [10] Siegelaar, S.E., Holleman, F., Hoekstra, J.B., DeVries, J.H., Glucose variability; does it matter?. Endocr Rev 31 (2010), 171–182.
11. [11] Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D.B., Wahlund, P.O., Ribel, U., Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 29 (2012), 2104–2114.
12. [12] Ratner, R.E., Gough, S.C., Mathieu, C., Del Prato, S., Bode, B., Merseback, H., et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 15 (2013), 175–184.
13. [13] Vora, J., Christensen, T., Rana, A., Bain, S.C., Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther 5 (2014), 435–446.
14. [14] Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379 (2012), 1489–1497.
15. [15] Mannucci, E., Monami, M., Dicembrini, I., Piselli, A., Porta, M., Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis. J Endocrinol Invest 37 (2014), 477–495.
16. [16] Bradley, C., Diabetes Treatment Satisfaction Questionnaire (DTSQ). Bradley, C., (eds.) Handbook of psychology and diabetes, 1994, Harwood, Chur, Switzerland, 111–132.
17. [17] Nicolucci, A., Giorgino, R., Cucinotta, D., Zoppini, G., Muggeo, M., Squatrito, S., et al. Validation of the Italian version of the WHO-Well-Being Questionnaire (WHO-WBQ) and the WHO-Diabetes Treatment Satisfaction Questionnaire (WHO-DTSQ). Diabetes Nutr Metab 17 (2004), 235–243.
18. [18] Gonder-Frederick, L.A., Schmidt, K.M., Vajda, K.A., Greear, M.L., Singh, H., Shepard, J.A., et al. Psychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes. Diabetes Care 34 (2011), 801–806.
19. [19] Wojcicki, J.M., J“J”-index. A new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res 27 (1995), 41–42.
20. [20] Kovatchev, B.P., Otto, E., Cox, D., Gonder-Frederick, L., Clarke, W., Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 29 (2006), 2433–2438.
21. [21] Baghurst, P.A., Calculating the mean amplitude of glycemic excursion from continuous glucose monitoring data: an automated algorithm. Diabetes Technol Ther 13 (2011), 296–302.
22. [22] McDonnell, C.M., Donath, S.M., Vidmar, S.I., Werther, G.A., Cameron, F.J., A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 7 (2005), 253–263.
23. [23] Kovatchev, B., Straume, M., Cox, D., Farhy, L.S., Risk analysis of blood glucose data: a quantitative approach to optimizing the control of insulin dependent diabetes. J Theor Med 3 (2000), 1–10.
24. [24] Christiansen, M., Bailey, T., Watkins, E., Liljenquist, D., Price, D., Nakamura, K., et al. A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system. Diabetes Technol Ther 15 (2013), 881–888.
25. [25] Rigato, M., Avogaro, A., Fadini, G.P., Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study. J Endocrinol Invest 38 (2015), 1357–1363.
26. [26] Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., Haahr, H., Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 14 (2012), 859–864.
27. [27] Cryer, P.E., The barrier of hypoglycemia in diabetes. Diabetes 57 (2008), 3169–3176.
28. [28] Urakami, T., Kuwabara, R., Aoki, M., Okuno, M., Suzuki, J., Efficacy and safety of switching from insulin glargine to insulin degludec in young people with type 1 diabetes. Endocr J 63 (2016), 159–167.
29. [29] Kusunoki, Y., Katsuno, T., Miyakoshi, K., Ikawa, T., Nakae, R., Ochi, F., et al. Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus. Diabetes Ther 4 (2013), 461–472.
30. [30] Tosaka, Y., Kanazawa, A., Ikeda, F., Iida, M., Sato, J., Matsumoto, K., et al. Switching from twice-daily basal insulin injections to once-daily insulin degludec injection for basal-bolus insulin regimen in Japanese patients with type 1 diabetes: a pilot study. Int J Endocrinol, 2015, 2015, 176261.